Drug Trial Radar · NCT04971733
A Study to Assess Safety and Target Engagement of E2814 in Participants With Mild to Moderate Cognitive Impairment Due to Dominantly Inherited Alzheimer's Disease
Last checked: Nov 19, 2026Latest source record: Jun 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
8
Actual
Start
Jun 28, 2021
Primary completion
May 24, 2024
Study completion May 24, 2024
Sponsor
- Lead sponsor
- Eisai Inc.Eisai
- Sponsor type
- Industry
- First posted
- Jul 21, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of the study is to assess the safety and tolerability of intravenous (IV) infusions of E2814 in participants with dominantly inherited Alzheimer's disease (DIAD), and to evaluate target engagement (TE) of E2814 on microtubule binding region (MTBR)-tau species in cerebrospinal fluid (CSF) in participants with DIAD.
Conditions
- Alzheimer Disease
Interventions
E2814Drug
E2814 intravenous infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs) and Serious TEAEsTime frame: From first dose of study drug up to 120 weeks
- Number of Participants With Markedly Abnormal Laboratory ValuesTime frame: From first dose of study drug up to 120 weeks
- Number of Participants With Clinically Significant Change in Vital Signs ValuesTime frame: From first dose of study drug up to 120 weeks
- Number of Participants With Clinically Significant Change in Electrocardiogram (ECG) FindingsTime frame: From first dose of study drug up to 120 weeks
- Cohort A: Change From Baseline in Cerebrospinal Fluid (CSF) Free, CSF Bound and Total Microtubule Binding Region of Tau (MTBR-tau; Starting at Amino Acid 354 and 299) at 12 WeeksTime frame: Pre-dose at Week 12
Locations
3 sites in 2 countries. Site status is shown where the registry gives one.
UC San Diego Altman Clinical and Translational Research Insititute Clinic
La Jolla, California
Indiana University School of Medicine, Health Partners, Adult Neurology Clinic
Indianapolis, Indiana
National Hospital for Neurology and Neurosurgery (NHNN) University College London(UCL) Hospitals NHS Foundation Trust
London, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.